You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 22, 2024

CLINICAL TRIALS PROFILE FOR EPLERENONE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Eplerenone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00082589 ↗ The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure Completed Pfizer Phase 4 2004-04-01 The purpose of this study is to determine if eplerenone is effective in the treatment of mild to moderate heart failure
NCT00082589 ↗ The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure Completed Pfizer's Upjohn has merged with Mylan to form Viatris Inc. Phase 4 2004-04-01 The purpose of this study is to determine if eplerenone is effective in the treatment of mild to moderate heart failure
NCT00094302 ↗ Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 2006-08-01 The purpose of this study is to evaluate the effectiveness of aldosterone antagonist therapy in reducing cardiovascular mortality, aborted cardiac arrest, and heart failure hospitalization in patients who have heart failure with preserved systolic function.
NCT00094302 ↗ Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function Completed HealthCore-NERI Phase 3 2006-08-01 The purpose of this study is to evaluate the effectiveness of aldosterone antagonist therapy in reducing cardiovascular mortality, aborted cardiac arrest, and heart failure hospitalization in patients who have heart failure with preserved systolic function.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Eplerenone

Condition Name

Condition Name for Eplerenone
Intervention Trials
Hypertension 27
Heart Failure 11
Central Serous Chorioretinopathy 4
Essential Hypertension 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Eplerenone
Intervention Trials
Hypertension 29
Heart Failure 24
Renal Insufficiency, Chronic 9
Kidney Diseases 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Eplerenone

Trials by Country

Trials by Country for Eplerenone
Location Trials
United States 208
Japan 46
Canada 30
United Kingdom 20
Germany 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Eplerenone
Location Trials
Massachusetts 15
Tennessee 13
Ohio 11
California 11
Florida 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Eplerenone

Clinical Trial Phase

Clinical Trial Phase for Eplerenone
Clinical Trial Phase Trials
Phase 4 43
Phase 3 19
Phase 2/Phase 3 4
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Eplerenone
Clinical Trial Phase Trials
Completed 66
Unknown status 15
Terminated 14
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Eplerenone

Sponsor Name

Sponsor Name for Eplerenone
Sponsor Trials
Pfizer 17
Brigham and Women's Hospital 13
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 8
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Eplerenone
Sponsor Trials
Other 168
Industry 53
NIH 9
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.